Mass General Brigham

Investment Strategy

Mass General Brigham is an integrated academic health care system headquartered in Somerville, Massachusetts, managing approximately $8 billion in endowment and investment assets. The system was founded in 1994 as Partners HealthCare through the merger of two of Boston’s most prestigious hospitals, Massachusetts General Hospital (founded in 1811) and Brigham and Women’s Hospital (formed in 1980 through a merger of three earlier institutions). The system rebranded to Mass General Brigham in 2019.

Mass General Brigham is the largest hospital-based research enterprise in the United States, with annual research expenditures exceeding $2 billion. The system’s member institutions include Massachusetts General Hospital, Brigham and Women’s Hospital, McLean Hospital, Spaulding Rehabilitation Hospital, and several community hospitals and research institutes across eastern Massachusetts. The system is closely affiliated with Harvard Medical School, and many of its physicians hold joint appointments.

The endowment supports the system’s research programs, educational initiatives, and capital investments. The investment portfolio is diversified across public equities, fixed income, private equity, venture capital, hedge funds, and real estate. At $8 billion, the endowment is managed with the institutional rigor of a large university endowment, employing an internal investment team that works under the direction of the system’s investment committee.

The portfolio’s construction reflects a long-term institutional investment horizon. Mass General Brigham’s financial position is supported by substantial operating revenues from patient care, which provides stability beyond the endowment. However, the endowment plays a critical role in funding research, attracting faculty, and supporting innovations that would not be possible through operating revenues alone.

Private Markets Approach

Mass General Brigham allocates an estimated 35% of its endowment to alternative investments, including private equity, venture capital, hedge funds, and real estate. The alternatives allocation reflects the endowment’s scale and perpetual time horizon, which support meaningful exposure to illiquid strategies.

The system’s location in Boston, one of the world’s most concentrated life sciences and biotech ecosystems, gives the investment team differentiated access to health care and life sciences investment opportunities. The Longwood Medical Area, Kendall Square, and the broader Route 128 corridor are home to hundreds of biotech companies, pharmaceutical research operations, and health care technology startups, many of which have direct relationships with Mass General Brigham researchers and clinicians.

The private equity program includes commitments to buyout, growth equity, and venture capital funds. The system’s deep connections to the biomedical research community provide informational advantages when evaluating health care-focused funds, particularly in therapeutics, medical devices, diagnostics, and health care IT. Mass General Brigham’s researchers generate a significant pipeline of intellectual property and potential commercialization opportunities that intersect with the venture capital ecosystem.

Mass General Brigham has also engaged in health care innovation through institutional venture activities. The system’s innovation programs work to translate clinical research into commercial products and services, creating a pipeline of health care startups that complement the endowment’s external fund commitments.

Real estate is a significant component of the portfolio, given the system’s extensive campus infrastructure across the Boston area and its ongoing capital expansion programs. Hedge fund allocations provide diversification and alternative return sources within the broader portfolio.

Fund managers seeking commitments should be prepared for sophisticated evaluation from a team with deep health care expertise. The system’s investment professionals can assess health care strategies with clinical-level understanding, making Mass General Brigham an informed and discerning LP for health care and life sciences fund managers.